Home > Resources > Whitepapers > Streamlining “Library-to-Lead” for your Antibody Therapeutics

Streamlining “Library-to-Lead” for your Antibody Therapeutics

June 6, 2018

The number of therapeutic antibodies entering the market continues to grow annually, with 2017 seeing ten approvals in either the European Union or the United States supported by a robust late-stage clinical pipeline that will likely yield even more approved drugs in 2018 and 2019. Making a drug is an expensive and time-consuming endeavor requiring an incredible level of detail and rigor to ensure that drugs are safe, efficacious, manufacturable and convenient to administer to the patient. While antibody generation is highly commoditized, with modern in vivo and in vitro libraries typically producing vast numbers of clones, the analytical tools used to characterize them at the molecular level to understand their mechanism of action often fall orders of magnitude behind in throughput.

Spotlight

Pathology Laboratories, Inc.

Established in Toledo, Ohio in 1946, Pathology Laboratories, Inc. (PathLabs) fostered a reputation among the area’s private medical practitioners as a provider of prompt, reliable and convenient laboratory testing services. Its status as a key partner in the delivery of quality medical care to the community was advanced in 1970 when PathLabs became the first independent medical laboratory in Ohio to seek and attain accreditation by the College of American Pathologists - the preeminent laboratory certifying body in the nation. Over the ensuing decades, PathLabs continued its tradition of uncompromising quality, personal service and overall excellence to become the dominant full-service independent medical laboratory in northwest Ohio and southeast Michigan. Since 2004, we have rapidly expanded our operations to other areas of Ohio including Cleveland, Columbus and Lima and their surrounding communities.

OTHER WHITEPAPERS

Simulation in the pharmaceutical industry

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.